Polyneuron Pharmaceuticals AG extended its Series A by CHF 14m bringing the total to CHF 36.5m. Polyneuron is a clinical stage developer of a new class of antigen-specific polymers for the treatment of patients affected by autoimmune diseases. HBM Healthcare Investments joins as additional investor to lead investor Sofinnova Partners and New Enterprise Associates. VISCHER advises Polyneuron with a team led by Matthias Staehelin (Partner) with Moritz Jäggy (Managing Associate), both Corporate.
21 September 2020